Literature DB >> 8077392

Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay.

L L Gheesling1, G M Carlone, L B Pais, P F Holder, S E Maslanka, B D Plikaytis, M Achtman, P Densen, C E Frasch, H Käyhty.   

Abstract

A standardized enzyme-linked immunosorbent assay (ELISA) was used by 11 laboratories to measure levels of total serum antibody to Neisseria meningitidis serogroup C capsular polysaccharide in 16 unpaired pre- and postvaccination serum samples. Twelve serum samples were from adults, and four were from children aged 2, 3, 5, and 9. The between-laboratory coefficient of variation for pre- and postvaccination sera ranged from 16 to 59% and 11 to 21%, respectively. The average percent difference (absolute value) from the between-laboratory means for all prevaccination sera measured by each laboratory was 24%, whereas the average percent difference was 13% for all postvaccination sera. A postvaccination quality control serum was diluted three times to give optical densities on the high, middle, and low portions of the standard reference curve. The three dilutions were assayed by the 11 laboratories a total of 241 times and yielded an overall coefficient of variation of 20%. Antibody-binding inhibition curves showed that the standardized ELISA was specific for N. meningitidis serogroup C capsular polysaccharide antibody. Fifty percent inhibition of seven serum samples was obtained after reaction with an average concentration of 0.9 micrograms of meningococcal serogroup C polysaccharide per ml; an average of 93% inhibition was obtained with 50 micrograms of polysaccharide per ml. The acceptance and use of this standardized ELISA will reduce between-laboratory assay variability and ensure a more accurate and reproducible assessment of immunogenicity for vaccines under development.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077392      PMCID: PMC264022          DOI: 10.1128/jcm.32.6.1475-1482.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  A quantitative immunochemical measure of the primary interaction between I BSA and antibody.

Authors:  R S FARR
Journal:  J Infect Dis       Date:  1958 Nov-Dec       Impact factor: 5.226

2.  A fractionating column for analysis of nucleic acids.

Authors:  J D MANDELL; A D HERSHEY
Journal:  Anal Biochem       Date:  1960-06       Impact factor: 3.365

3.  Caveats and suggestions for the ELISA.

Authors:  F H Pruslin; S E To; R Winston; T C Rodman
Journal:  J Immunol Methods       Date:  1991-03-01       Impact factor: 2.303

4.  Prevalence of meningococcal serogroups and description of three new groups.

Authors:  J R Evans; M S Artenstein; D H Hunter
Journal:  Am J Epidemiol       Date:  1968-05       Impact factor: 4.897

5.  Quantitation of human IgG subclass antibodies to Haemophilus influenzae type b capsular polysaccharide. Results of an international collaborative study using enzyme immunoassay methodology.

Authors:  D J Herrmann; R G Hamilton; T Barington; C E Frasch; G Arakere; O Mäkelä; L A Mitchell; J Nagel; G T Rijkers; B Zegers
Journal:  J Immunol Methods       Date:  1992-04-08       Impact factor: 2.303

6.  An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay.

Authors:  D C Phipps; J West; R Eby; M Koster; D V Madore; S A Quataert
Journal:  J Immunol Methods       Date:  1990-12-31       Impact factor: 2.303

7.  Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C.

Authors:  P Costantino; S Viti; A Podda; M A Velmonte; L Nencioni; R Rappuoli
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

8.  Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers.

Authors:  G Arakere; C E Frasch
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

9.  Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay.

Authors:  G M Carlone; C E Frasch; G R Siber; S Quataert; L L Gheesling; S H Turner; B D Plikaytis; L O Helsel; W E DeWitt; W F Bibb
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

10.  Characterization of the serum antibody response to the capsular polysaccharide of Haemophilus influenzae type b in children with invasive infections.

Authors:  B Trollfors; T Lagergård; B A Claesson; E Thornberg; J Martinell; R Schneerson
Journal:  J Infect Dis       Date:  1992-12       Impact factor: 5.226

View more
  48 in total

1.  Assignment of additional anticapsular antibody concentrations to the Neisseria meningitidis group A, C, Y, and W-135 meningococcal standard reference serum CDC1992.

Authors:  Cheryl M Elie; Patricia K Holder; Sandra Romero-Steiner; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

2.  Meningococcal group C conjugate vaccines.

Authors:  J Maclennan
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

3.  An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study.

Authors:  B D Plikaytis; D Goldblatt; C E Frasch; C Blondeau; M J Bybel; G S Giebink; I Jonsdottir; H Käyhty; H B Konradsen; D V Madore; M H Nahm; C A Schulman; P F Holder; T Lezhava; C M Elie; G M Carlone
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

4.  Development of antibodies against tetravalent meningococcal polysaccharides in revaccinated complement-deficient patients.

Authors:  M Drogari-Apiranthitou; C A Fijen; D Van De Beek; E F Hensen; J Dankert; E J Kuijper
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

5.  Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines.

Authors:  Kazutoyo Miura; Andrew C Orcutt; Olga V Muratova; Louis H Miller; Allan Saul; Carole A Long
Journal:  Vaccine       Date:  2007-11-20       Impact factor: 3.641

6.  Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.

Authors:  Dominic F Kelly; Matthew D Snape; Kirsten P Perrett; Elizabeth A Clutterbuck; Susan Lewis; Geraldine Blanchard Rohner; Meryl Jones; Ly-Mee Yu; Andrew J Pollard
Journal:  Immunology       Date:  2009-05       Impact factor: 7.397

7.  Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.

Authors:  Paul Balmer; Michelle Falconer; Paula McDonald; Nick Andrews; Emily Fuller; Christine Riley; Edward Kaczmarski; Raymond Borrow
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Immunization of female mice with glycoconjugates protects their offspring against encapsulated bacteria.

Authors:  Margret Y Richter; Håvard Jakobsen; Alda Birgisdottir; Jean-François Haeuw; Ultan F Power; Giuseppe Del Giudice; Antonella Bartoloni; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Purified capsular polysaccharide of Neisseria meningitidis serogroup A as immune potentiator for antibody production.

Authors:  Tamara Menéndez; Tania Carmenate; Yoelys Cruz-Leal; Edelgis Coizeau; Evelyn Caballero; Daniel Bello; María Guirola; Anabel Alvarez; Gerardo Guillén
Journal:  Curr Microbiol       Date:  2009-09-23       Impact factor: 2.188

10.  Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine.

Authors:  Ray Borrow; Nick Andrews; Helen Findlow; Pauline Waight; Joanna Southern; Annette Crowley-Luke; Lorraine Stapley; Anna England; Jamie Findlow; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2009-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.